88 results about "Metabolic markers" patented technology

The invention provides methods, reagents and systems to preferentially mark fast-proliferating cells / tissues (such as cancer), by incorporating non-natural amino acids into proteins, preferably in vivo, using the endogenous protein synthesis machinery of an organism. The incorporated non-natural amino acids contain reactive groups for further chemical reagents, which may serve as a “handle” to for a number of uses, such as imaging of cancer cells, targeting drugs to preferentially kill cancer cells, and proteomic analysis in the context of large scale or high throughput screening for candidate drug leads that affects the proliferation of a target cell, etc.

Novel methods for assessing the state of a diabetic condition of a subject are described, comprising determining the amount of a metabolite in a sample from a body fluid or tissue of the subject. The methods may be used, for example, in diagnosing and monitoring insulin resistance, prediabetes, or the response to a drug which alters a diabetic condition.

The invention discloses a diagnosis marker suitable for an early-stage esophageal squamous cell cancer diagnosis and a screening method of the diagnosis marker. Twenty five kinds of serum metabolic markers and ten relevant metabolic pathways are discovered; through the combination of the twenty five kinds of serum metabolic markers, the diagnosis marker used for an esophagus cancer diagnosis can be obtained. The screening method of the diagnosis marker has high operability; the diagnosis marker can be used for building a diagnosis model; the diagnosis model has the advantages of good effect, high sensitivity and good specificity, is suitable for a late-stage esophagus cancer diagnosis and is also suitable for the early-stage esophagus cancer diagnosis. The diagnosis model built by adopting the diagnosis marker provided by the invention has the advantages that the diagnosis can be realized only through blood sampling; the noninvasive effect is achieved; the cost is low; the modern internal invasive diagnosis mode can be well replaced; the pain of a patient is greatly reduced; in addition, the diagnosis speed is high; convenience is realized; the required time is short; the work efficiency is improved; the early discovery and early treatment of an esophagus cancer can be favorably realized; good clinic use and popularization value is realized.

The invention provides a method for joint detection of metabolic markers based on ultra high performance liquid chromatography-tandem mass spectrometry. Qualitative and quantitative analysis of more than 134 metabolites including amino acids and carnitines is completed only through one-time detection of only an extremely low amount, being 3 [mu]L, of a blood sample by adopting an isotope-labeled amino acid standard substance and an isotope-labeled carnitine standard substance as internal standard substances, a high-concentration quality control blood tablet and a low-concentration quality control blood sheet as positive control substances and an acetonitrile-water solution as a mobile phase through reasonably setting parent ion scanning, neutral loss scanning and multi-reaction ion monitoring scanning combined ultra performance liquid chromatograph-tandem mass spectrometer detection conditions. The method has the advantages of small sample volume, high sensitivity, high accuracy, highthroughput and high repeatability, and is suitable for large-scale analysis of clinical dried blood tablet samples.

The invention discloses a method for predicating the metabolizable energy level of pig diets by a metabonomics technology. The method is characterized in that the relative content of one to seven of eight plasma metabolic markers of a pig to be tested is plugged in equations with one to seven unknown quantities established in the invention to obtain the predicted value of metabolizable energy of the diets of the pig to be tested, wherein the plasma metabolic markers include lysophosphatidylcholine (18:3 / 0:0), myristoyl lysophosphatidylcholine (14:0 / 0:0), glycerophosphorylethanolamine (18:0 / 0:0), lysophosphatidylcholine (20:4 / 20:4), proline, phosphatidylcholine (18:2 / 0:0), arginylphenylalanylarginine and glycerophosphorylethanolamine (18:1(9Z) / 0:0), and the relative deviation between the predicted value obtained from the equation with seven unknown quantities and an actual value does not exceed + / -1 percent. The method has significant theoretical and practical significances for evaluating the nutritional status and optimizing the formula in time, meeting the nutritional requirements of pigs under physiological and pathological conditions in different environments and improving the production efficiency of pigs.

The invention belongs to the technical field of metabonomics, and provides Xiaoyao San metabolic markers in a biological sample, and a detection method and an application thereof. A pharmacological action mechanism of Xiaoyao San for treating depression is defined. The metabolic markers are 4-oxo hex-2-ene dioic acid, creatinine, L-cystathionine and acetylphosphate. A UPLC-Q-TOF / MS technology is adopted for analyzing the plasma and metabolic profile change of patients in a drug administration group and a control group of the Xiaoyao San, and then a multivariate statistical analysis method and an orthogonal partial least square discriminant analysis (OPLS-DA) method are adopted for screening the changes of the metabolic markers of the Xiaoyao San after 8-week treatment. The study is used as a first clinical metabonomics study of the Xiaoyao San; the influence of the metabolic level of the Xiaoyao San is found; the action mechanism of the Xiaoyao San is preliminarily illuminated in metabolic pathway; and a new method is provided for predicting the pharmacological mechanism of the Xiaoyao San for treating the depression.

The invention discloses a use of endogenous metabolites as markers for predicting the prognosis risk of coronary heart disease or in preparation of a kit for predicting the prognosis risk of coronaryheart disease. The metabolite marker can effectively predict the risk of death and major adverse cardiovascular events (MACE) in patients with coronary heart disease and the risk of cardiac insufficiency, and has the characteristics of specificity, sensitivity, high efficiency and non-invasiveness. After the metabolite marker is used for predicting the prognosis survival rate of patients with coronary heart disease, the AUC is 65% or more. Through combination, the AUC is close to 100% compared with AUC based on the single marker and the prediction effect is good. The method for detecting through the marker has high sensitivity, is convenient and quick and produces accurate and reliable results. The predictive model constructed by the marker can be used for predicting the prognosis risk ofcoronary heart disease, has good predictive effects and high sensitivity, is convenient, rapid and non-invasive and has an important clinical application value.

The invention discloses applications of metabolic markers in diagnosing and identifying benign or malignant lesions of thyroid gland. The malignant lesions of thyroid gland are used for referring thyroid cancer, and the benign lesions of thyroid gland are used for referring thyroid benign node; and the metabolic markers are 1-oleoyl-sn-glycerol-3-phosphatidylcholine and / or 1-stearoyl-sn-glycerol-3-phosphatidylcholine. It is confirmed that when 1-oleoyl-sn- glycerol-3-phosphatidylcholine and 1-stearoyl-sn-glycerol-3-phosphatidylcholine are used for diagnosing and identifying thyroid cancer and thyroid benign node separately, certain accuracy is achieved; and when 1-oleoyl-sn- glycerol-3-phosphatidylcholine and 1-stearoyl-sn-glycerol-3-phosphatidylcholine are used for diagnosing and identifying thyroid cancer and thyroid benign node together, higher accuracy is achieved; so that 1-oleoyl-sn- glycerol-3-phosphatidylcholine and 1-stearoyl-sn-glycerol-3-phosphatidylcholine, and a composition of 1-oleoyl-sn- glycerol-3-phosphatidylcholine and 1-stearoyl-sn-glycerol-3-phosphatidylcholine can be taken as the metabolic markers in diagnosing and identifying thyroid cancer and thyroid benign node.

The invention provides an identification and analysis method for coronary heart disease urine metabolic markers, and relates to an identification and analysis method for urine metabolic markers. The identification and analysis method for the coronary heart disease urine metabolites can be used for solving the problems of low efficiency, high expenses and incapability of realizing early detection and early treatment of an existing coronary heart disease detection method. The identification and analysis method comprises the following steps: 1, collecting and preprocessing a urine sample; 2, preparing the urine sample; 3, performing UPLC separation; 4, directly injecting the urine sample subjected to UPLC separation into a mass spectrometer without shunting, and performing cationic and anionic scanning analysis on the urine sample subjected to UPLC separation; 5, identifying urine biomarkers, thereby obtaining 39 potential urine biomarkers; 6, performing metabolism pathway analysis on the 39 potient urine biomarkers, thereby obtaining 19 metabolic pathways; and 7, further determining biomarkers related to the coronary heart disease according to the size of AUC by use of ROC curve analysis. The identification and analysis method is applied to the field of identification on metabolic markers.

The invention belongs to the technical field of medical biology, and relates to application of plasma metabolic markers in diagnosis or monitoring of HBV. The application of the plasma metabolic markers in the diagnosis or monitoring of the HBV aims to provide the application of the metabolic markers in blood in the preparation of reagents for diagnosing or monitoring a hepatitis B virus, wherein,the markers are one or more than one of Creatinine, L-Proline, L-Arginine, PC (P-16:0 / 20:4 (8Z, 11Z, 14Z, 17Z)), PE (18:2 (9Z, 12Z) / 18:1 (9Z), PC (o-16:1 (9Z) / 18:2 (9Z, 12Z), PC (P-16:0 / 18:1 (11Z), PE (18:2 (9Z, 12Z) / 18:0), PE (P-16:0 / 22:4 (7Z, 10Z, 13Z, 16Z), PE (P-16:0 / 22:4 (7Z, 10Z, 13Z, 16Z), PE (P-18:0 / 18:2 (9Z, 12Z)), PE(18:0 / 18:1 (11Z), LysoPE (18:0 / 0:0), PE (16:0 / 18:1 (11Z), or PE (18:2 (9Z, 12Z) / 16:0).

The invention discloses a metabolic marker group for diagnosing a coronary heart disease. The metabolic marker group comprises one or more of citramalic acid, methionine, taurine, malic acid, phenylalanine and linoleic acid. In a ROC (receiver operating characteristic) curve evaluation method, under the condition that the AUC (area under curve) is larger than 0.5, the closer the AUC is to 1, the better the diagnosis effect is. A metabolic marker has lower accuracy when the AUC is 0.5-0.7, has certain accuracy when the AUC is 0.7-0.9 and has higher accuracy when the AUC is 0.9 or larger. Verification proves that when the single metabolic marker in the metabolic marker group is used for diagnosing and distinguishing patients with the coronary heart disease from subjects with normal coronary arteries, or diagnosing and distinguishing the patients with the coronary heart disease from patients with coronary atherosclerosis, the AUCs are all 0.7 or larger; when a plurality of the metabolic markers are used in combination, the AUC is closer to 1 than that when the single metabolic marker is used, so that the diagnosis effect is better; when six metabolic markers are used in combination, the AUC is closest to 1, and diagnosing and distinguishing effects are the best.

The invention provides a metabonomics network marker identification method based on a horizontal relation, belongs to the technical field of biological data analysis, and relates to a metabonomics data analysis method DNB-HC for screening potential network markers of complex diseases. The horizontal relation between the features is defined by using probability scores and is used for measuring thesize relation of the relative expression levels of a pair of metabolic features in the same sample, and the robustness of the horizontal relation is determined through a random disturbance test, so that the network connection edge is determined. Besides, the network markers are identified by using a difference network analysis method, and the screened network metabolic markers have relatively gooddistinguishing capability, so that a practical and effective data processing means can be provided for researching a disease occurrence and development mechanism and diagnosing diseases.

The invention relates to a method for detecting small-molecule metabolic markers in the peripheral blood of aortic dissection, and its application. Combined chromatography and mass spectrometry are employed for high-flux large-scale metabonomic analysis of patients with aortic dissection to determine small-molecule metabolic profiling of the peripheral blood of the aortic dissection, and three small-molecule metabolic markers with greatest difference is obtained, wherein the three small-molecule metabolic markers are N1-acetyl-N2-formyl-5-methoxy kynurenine, glycerophosphorylcholine and 2-mercaptohistidine betaine. The invention provides a simple, low-harm and cheap method for screening and diagnosis of aortic dissection, and effective reference bases can be provided for diagnosis of clinical patients and assessment of the treatment efficacy of drugs.

The invention discloses a diagnosis marker suitable for an early-stage esophageal squamous cell cancer diagnosis. The diagnosis marker is a composition of two or more than two kinds of materials from the following five kinds of serum metabolic markers including L-tyrosine, L-tryptophan, glycocholic acid, taurocholate and cortisol. When the diagnosis marker provided by the invention is adopted, a diagnosis model can be built. The diagnosis model has the advantages of good effect, high sensitivity and good specificity, is suitable for late-stage and early-stage esophagus cancer diagnoses, and has good clinic use and popularization value.

The invention provides a tissue metabolism network research method for a toxic effect of atmospheric particulate matters, wherein the method includes the following steps: S1, collecting atmospheric particulate matters in a research area and preparing an atmospheric particulate matter suspension; S2, carrying out intratracheal instillation on the atmospheric particulate matter suspension into a tested animal body to simulate the exposure of a human body to the atmospheric particulate matters; S3, after the end of the experiment period, collecting the liver, lung and serum of the tested animal;S4, carrying out metabolome analysis of the liver, lung and serum through a liquid chromatography-mass spectrometry combined platform, and determining labeled metabolites of the liver, lung and serumrespectively; and S5, determining key metabolic network through the correlation analysis and the network analysis, and determining key labeled metabolites by the network node centrality evaluation. With use of network analysis, key metabolic markers of multiple tissues are determined through a network model, a method is provided for identifying key marker metabolites in multiple tissue metabolismdata under different phenotypes, and the accuracy of identification of the metabolic markers is improved.

The invention discloses metabolic markers for liver and gall disease diagnosis and a screening method thereof. The metabolic markers comprise a serum metabolic marker and a urine metabolic marker; theserum metabolic marker comprises one or any combination of EPA, AA, DHA, TCDA, DCA, GCA, TCA, GCDA, GCDCA, GDCA, CDCA, LPC16-0, LPC18-0, LPC18-1, LPC20-0. According to the screening method, a pre-established LC-MS / MS method is utilized to quantitatively detect the content of target metabolites in a clinical large sample (serum and urine), and a diagnostic marker is screened. The metabolic markerprovided by the invention can effectively diagnose liver and gall diseases, reduce the omission ratio of liver cancer and bile duct cancer, is very beneficial to early diagnosis and early treatment ofliver cancer and bile duct cancer, is greatly helpful for improving prognosis of liver cancer and bile duct cancer and reducing the mortality of liver cancer and bile duct cancer, and has good clinical application and popularization values. In practical application, more samples and more metabolite combinations can be selected for modeling according to the modeling method disclosed by the invention, so that the accuracy of the model is improved.

The invention discloses an application of a group of metabolic markers in early diagnosis of a metabolic syndrome. The metabolic markers at least comprise glutamine-leucine and phosphatidyl ethanolamine PE (18:2(9Z,12Z) / P-18:0), and further comprise tyrosine or phenylalanine. In a validation set of a specific embodiment, the accuracy degree for distinguishing a health volunteer and a metabolic syndrome patient through joint use of tyrosine, phosphatidyl ethanolamine PE (18:2(9Z,12Z) / P-18:0) and glutamine-leucine reaches 80.5%, and the accuracy degree for distinguishing the health volunteer andthe metabolic syndrome patient through joint use of phenylalanine, glutamine-leucine and phosphatidyl ethanolamine PE (18:2(9Z,12Z) / P-18:0)reaches 82.6%. Therefore, the abovementioned metabolic markers have high accuracy degree for diagnosis of the metabolic syndrome, can be prepared into a metabolic syndrome diagnosis kit and are used for early diagnosis of a healthy person suffering from the metabolic syndrome.

The invention relates to an amino acid metabolomics-based method for researching an anti-insomnia action mechanism of sugemule. Amino acid metabolome in each of tissues of the brains of para-chlorophenylalanine (PCPA) insomnic model rats before and after gavage with the sugemule is analyzed by applying a gas chromatography-mass spectrometer (GC-MS) method; endogenous compounds are identified by astandard fingerprint bank; changes of metabolite maps of all parts of the brains are analyzed and related metabolic markers are assayed by employing principal component analysis (PCA) and partial least squares-discrimination analysis (PLS-DA) modes; a targeting metabolomics research is conducted by applying liquid chromatograph-mass spectrometer (LC-MS) to explore content changes of neurotransmitters including 5-hydroxytryptamine, gamma-aminobutyric acid (GABA), glutamic acid (Glu) and the like in the brain tissues and related metabolites; by seeking for difference metabolites related with thecurative effect of the sugemule and metabolic pathways of the difference metabolites from brain tissue samples of clinical rats, the anti-insomnia action mechanism and an action site of the sugemuleare specified; and a metabolomics research means is applied for the first time by the amino acid metabolomics-based method to preliminarily confirm the action mechanism of the sugemule regulating andcontrolling a sleep-wake rhythm by a neurotransmitter system.

The invention discloses a diagnosis marker suitable for an esophagus cancer early-stage diagnosis. The diagnosis marker is a combination of two or more than two kinds of materials from the following seven kinds of serum metabolic markers including LPA (lysophosphatidic acid) [18 to 1(9Z) / 0 to 0], LysoPC (lysolecithin) (14 to 0 / 0 to 0), LysoPC (lysolecithin) [18 to 2(9Z,12Z)], LysoPC (lysolecithin) (24 to 0), phospholipids PC [14 to 1(9Z) / P-18 to 1(11Z)], phospholipids PC [16 to 0 / 18 to 2(9Z,12Z)] and phospholipids PC [24 to 1(15Z) / 22 to 6(4Z,7Z,10Z,13Z,16Z,19Z)]. When the diagnosis marker provided by the invention is adopted, a diagnosis model can be built. The diagnosis model has the advantages of good effect, high sensitivity and good specificity, is suitable for late-stage and early-stage esophagus cancer diagnoses, and has good clinic use and popularization value.

The invention discloses a detection kit of methotrexate metabolism markers, and a detection method and application of the detection kit. The kit is used for detecting the gene polymorphism of the methotrexate metabolism markers ABCB1 (C3435T), MTHFR (C677T) and SLCO1B1 (c.1865+4846T>C). According to the invention, multiple RPA amplification and optimized pyrosequencing technologies are combined to detect the methotrexate drug dosage and the gene polymorphism related to adverse reaction prediction, the kit can be used for simultaneously detecting ABCB1 (C3435T), MTHFR (C677T) and SLCO1B1 (c.1865+4846T>C) gene polymorphism methotrexate drugs, and suggestions from the gene perspective are provided for clinical personalized medication.

The invention discloses application of three metabolic markers independently or jointly in preparation of a kit for diagnosing systemic lupus erythematosus. The metabolic markers which are arabitol, asparagine and stearic acid provided by the invention can be used for diagnosing and distinguishing healthy people and systemic lupus erythematosus patients independently or by combining any two or three of the metabolic markers, and the diagnosis accuracy is high, so that the metabolic markers have the prospect of being developed and prepared into a kit for diagnosing systemic lupus erythematosus. In addition, the diagnostic index provided by the invention is serum metabolite, can be detected only by taking a small amount of blood, and is basically noninvasive.

The invention relates to methods for the diagnosis of non-alcoholic steatosis (NASH). The method relies on the determination of certain metabolic markers in a biological sample of the patient which are up- or down-regulated in the NASH patients vs. patients with a simple fatty liver (steatosis).

Discloses is a process for detecting and evaluating metabolic disturbances and specific nutrient insufficiencies within an individual. The bio-chemical pathways of the individual are challenged by consuming an oral amino acid supplement prior to urine sample collection. The oral amino acid supplement includes at least two of the amino acids selected from the group: L-Valine, L-Leucine, L-Isoleucine, L-Tryptophan, L-Histidine, and L-Alanine. After processing the amino acid supplement, a urine sample is collected and a urinary organic acid profile is evaluated. The levels of metabolic markers within the organic acid profile are evaluated to determine the presence of metabolic disturbances, nutrient insufficiencies, genetic impairments, toxicant impairments, mitochondrial function impairment, or small intestinal dysbiosis, within the individual.

The invention discloses application of a group of metabolic markers in early diagnosis of coronary heart disease events of patients with metabolic syndrome. Metabolic syndrome is a high risk factor for the coronary heart disease, and patients with metabolic syndrome are at higher risk of the coronary heart disease. Through the application disclosed by the invention, a group of metabolic markers comprising histidine, phosphatidylcholine PC (16:0 / 16:0), lysophosphatidylcholine lysoPC (17:0) and hypoxanthine is discovered and can be used for diagnosing and distinguishing patients suffering from metabolic syndrome and patients suffering from the coronary heart disease, and the metabolic markers further can be used for preparing a kit for early diagnosing the occurrence of the coronary heart disease events of the patients suffering from metabolic syndrome.

The invention relates to the field of biochemistry, in particular to a nucleic acid metabolism marker detection method based on a 4-thio-nucleoside oxidative aminolysis reaction and a sequencing technology. The invention provides a converted product 5-R1-N4-R2-2'-deoxycytidine (5-R1-N4-R2-dC) of 5-R1-4-thio-2'-deoxyuridine (5-R1-4SdU) in nucleic acid, an oxidative aminolysis reaction for preparing the product and a method for determining metabolism labeled nucleic acid of the 5-R1-4SdU based on the reaction. The 5-R1-4SdU in the nucleic acid and the converted product 5-R1-N4-R2-dC thereof have the hydrogen bond mode difference, the difference can be represented by using a sequencing means, the difference is represented as the T-C mutation of the 5-R1-4SdU site in the nucleic acid before and after the reaction, and dynamic information about the nucleic acid synthesis or repair is obtained based on the measured T-C mutation generation position and the determined T-C mutation generation frequency.

The invention discloses metabolic markers for prognosis of hepatitis B acute-on-chronic liver failure and a screening method of the metabolic markers. The screening method comprises the steps: (1) collecting an HBV-ACLF serum sample; (2) detecting metabolome of the serum sample by using an ultra-high performance liquid chromatography-mass spectrometry (UPLC-MS); (3) comparing metabolome in liver tissues of healthy control and chronic hepatitis B patients, and analyzing and processing data to obtain HBV-ACLF biomarkers; and (4) determining biomarkers with a death risk from the HBV-ACLF biomarkers in the step (3). The invention discloses the metabolic markers for prognosis of hepatitis B acute-on-chronic liver failure based on clinical data of a patient and metabonomics, and the metabolic markers are Gamma-Linolenic acid and Glutamylphenylalanine.

The invention discloses a rapid reaction kit for predicting the dosage of traserine, and a detection method and application thereof. The detection kit is used for detecting the gene polymorphism of two genes of traserine metabolic markers CYP2C19 681G>A and CYP2C19 636G>A. The kit comprises a CYP2C19 681G>A amplification primer, a CYP2C19 681G>A sequencing primer, a CYP2C19 636G>A amplification primer, a CYP2C19 636G>A sequencing primer and a positive control. According to the present invention, the multiple RPA amplification and the optimized pyrosequencing technology are combined to detect the gene polymorphism related to the traserine drug treatment effect prediction, and the kit can simultaneously detect the CYP2C19 (681G>A) gene polymorphism and the CYP2C19 (636G>A) gene polymorphism so as to provide the gene perspective suggestion for the clinical personalized medication.

The invention relates to a meconium metabolism marker and a screening method and application thereof, the meconium metabolism marker is used for evaluating neonatal jaundice, and the meconium metabolism marker comprises valine, leucine and isoleucine. The valine, the leucine and the isoleucine are closely related to the neonatal jaundice, and the occurrence of the neonatal jaundice can be reliably judged by detecting the metabolic markers. Therefore, whether the neonates are prone to jaundice or not can be judged at the first time only by detecting meconium excreted by the newly born neonates, relevant monitoring and intervention are carried out in time, judgment does not need to be carried out two or three days after the neonates are born, and early discovery, early intervention and early treatment are truly achieved.